Circular RNAs in Parkinson’s Disease: Reliable Biological Markers and Targets for Rehabilitation

[1]  F. Coppedè,et al.  Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics , 2022, Nature Reviews Neurology.

[2]  Boyan Fang,et al.  Association Between Mitochondrial Function and Rehabilitation of Parkinson's Disease: Revealed by Exosomal mRNA and lncRNA Expression Profiles , 2022, Frontiers in Aging Neuroscience.

[3]  Hong-ke Zhou,et al.  Circular RNA hsa_circ_0000437 may be used as a new indicator for the diagnosis and prognosis of hepatocellular carcinoma , 2022, Bioengineered.

[4]  Ji Li,et al.  Association of p53 with Neurodegeneration in Parkinson's Disease , 2022, Parkinson's disease.

[5]  I. Cameron,et al.  Aerobic Exercise Alters Brain Function and Structure in Parkinson's Disease: A Randomized Controlled Trial , 2021, Annals of neurology.

[6]  F. Cuetos,et al.  Unfolded p53 as a marker of oxidative stress in Mild Cognitive Impairment, Alzheimer's and Parkinson's disease. , 2021, Current Alzheimer Research.

[7]  Weiwei Tang,et al.  circCORO1C promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing the expression of PD‐L1 through NF‐κB pathway , 2021, Journal of clinical laboratory analysis.

[8]  N. Xiong,et al.  Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease , 2021, Frontiers in Immunology.

[9]  Yifeng Zhou,et al.  A peptide CORO1C-47aa encoded by the circular noncoding RNA circ-0000437 functions as a negative regulator in endometrium tumor angiogenesis , 2021, The Journal of biological chemistry.

[10]  J. Gan,et al.  CircFAM13B promotes the proliferation of hepatocellular carcinoma by sponging miR-212, upregulating E2F5 expression and activating the P53 pathway , 2021, Cancer cell international.

[11]  A. Mietelska-Porowska,et al.  Western diet as a trigger of Alzheimer’s disease: From metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration , 2021, Ageing Research Reviews.

[12]  James E. Tomkins,et al.  Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease , 2021, Annals of neurology.

[13]  T. Gasser,et al.  A Novel SNCA A30G Mutation Causes Familial Parkinsonʼs Disease , 2021, Movement disorders : official journal of the Movement Disorder Society.

[14]  D. Centonze,et al.  The microRNA let-7b-5p Is Negatively Associated with Inflammation and Disease Severity in Multiple Sclerosis , 2021, Cells.

[15]  L. Stefanis,et al.  Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease , 2021, Movement disorders : official journal of the Movement Disorder Society.

[16]  Boyan Fang,et al.  Efficacy of short-term multidisciplinary intensive rehabilitation in patients with different Parkinson’s disease motor subtypes: a prospective pilot study with 3-month follow-up , 2020, Neural regeneration research.

[17]  M. Liz,et al.  Linking Alpha-Synuclein to the Actin Cytoskeleton: Consequences to Neuronal Function , 2020, Frontiers in Cell and Developmental Biology.

[18]  S. Kadener,et al.  A Parkinson's disease CircRNAs Resource reveals a link between circSLC8A1 and oxidative stress , 2020, EMBO molecular medicine.

[19]  Yongyan Wu,et al.  Circular RNA circCORO1C promotes laryngeal squamous cell carcinoma progression by modulating the let-7c-5p/PBX3 axis , 2020, Molecular Cancer.

[20]  Jason J. Davis,et al.  Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  Jørgen Kjems,et al.  The biogenesis, biology and characterization of circular RNAs , 2019, Nature Reviews Genetics.

[22]  M. Smidt,et al.  Entanglement of Genetics and Epigenetics in Parkinson’s Disease , 2019, Front. Neurosci..

[23]  L. Bodin,et al.  Occupational Exposures and Neurodegenerative Diseases—A Systematic Literature Review and Meta-Analyses , 2019, International journal of environmental research and public health.

[24]  T. Carnwath,et al.  The direct and indirect effects of α-synuclein on microtubule stability in the pathogenesis of Parkinson’s disease , 2018, Neuropsychiatric disease and treatment.

[25]  Jian-ning Zhang,et al.  MicroRNA let-7c-5p improves neurological outcomes in a murine model of traumatic brain injury by suppressing neuroinflammation and regulating microglial activation , 2018, Brain Research.

[26]  T. Südhof,et al.  Cell Biology and Pathophysiology of α-Synuclein. , 2018, Cold Spring Harbor perspectives in medicine.

[27]  J. Kjems,et al.  Circular RNAs in cancer: opportunities and challenges in the field , 2017, Oncogene.

[28]  Li Yang,et al.  Coordinated circRNA Biogenesis and Function with NF90/NF110 in Viral Infection. , 2017, Molecular cell.

[29]  M. Islam,et al.  Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation. , 2017, Biochemical Society transactions.

[30]  A. Ascherio,et al.  The epidemiology of Parkinson's disease: risk factors and prevention , 2016, The Lancet Neurology.

[31]  T. Outeiro,et al.  The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease. , 2016, Brain : a journal of neurology.

[32]  Xiaolong Liu,et al.  The Coronin Family and Human Disease. , 2016, Current protein & peptide science.

[33]  Ya-Yun Wang,et al.  p53 and mitochondrial dysfunction: novel insight of neurodegenerative diseases , 2016, Journal of Bioenergetics and Biomembranes.

[34]  M. Sousa,et al.  The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders , 2016, Progress in Neurobiology.

[35]  M. Dinger,et al.  Endogenous microRNA sponges: evidence and controversy , 2016, Nature Reviews Genetics.

[36]  E. Duplan,et al.  Direct α-synuclein promoter transactivation by the tumor suppressor p53 , 2016, Molecular Neurodegeneration.

[37]  I. Ferrer,et al.  Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson’s disease , 2015, Acta neuropathologica communications.

[38]  J. Ruysschaert,et al.  Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. , 2015, The Biochemical journal.

[39]  S. Cherry,et al.  Combinatorial control of Drosophila circular RNA expression by intronic repeats, hnRNPs, and SR proteins , 2015, Genes & development.

[40]  Kirsten Potter,et al.  The Mini-Balance Evaluation Systems Test (Mini-BESTest). , 2015, Journal of physiotherapy.

[41]  E. Thompson.  Hamilton Rating Scale for Anxiety (HAM-A). , 2015, Occupational medicine.

[42]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[43]  P. Hof,et al.  The epigenetics of aging and neurodegeneration , 2015, Progress in Neurobiology.

[44]  Peter R Cook,et al.  Exon Skipping Is Correlated with Exon Circularization. , 2015, Journal of molecular biology.

[45]  J. O'Callaghan,et al.  Biomarkers of Parkinson's disease: present and future. , 2015, Metabolism: clinical and experimental.

[46]  C. van Broeckhoven,et al.  Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. , 2015, Trends in genetics : TIG.

[47]  Tim Schneider,et al.  Exon circularization requires canonical splice signals. , 2015, Cell reports.

[48]  F. Valtorta,et al.  GRP78 clustering at the cell surface of neurons transduces the action of exogenous alpha-synuclein , 2014, Cell Death and Differentiation.

[49]  Erin Long,et al.  Short-distance walking speed tests in people with Parkinson disease: reliability, responsiveness, and validity. , 2014, Gait & posture.

[50]  C. Wahlestedt,et al.  Non-coding RNAs as direct and indirect modulators of epigenetic regulation , 2014, Epigenetics.

[51]  Quanzheng Li,et al.  Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson’s disease , 2013, Neuroreport.

[52]  L. Bubacco,et al.  GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. , 2013, Human molecular genetics.

[53]  Gammon M Earhart,et al.  Five times sit-to-stand test performance in Parkinson's disease. , 2011, Archives of physical medicine and rehabilitation.

[54]  A. Schapira,et al.  Etiology and pathogenesis of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[55]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[56]  G. Schratt.  microRNAs at the synapse , 2009, Nature Reviews Neuroscience.

[57]  M. Parihar,et al.  Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. , 2009, The international journal of biochemistry & cell biology.

[58]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[59]  J. Jankovic.  Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[60]  B. Bloem,et al.  Evidence‐based analysis of physical therapy in Parkinson's disease with recommendations for practice and research , 2007, Movement disorders : official journal of the Movement Disorder Society.

[61]  B. Christie,et al.  Exercise-induced changes in dendritic structure and complexity in the adult hippocampal dentate gyrus , 2006, Neuroscience.

[62]  M. Farrer.  Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[63]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[64]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[65]  W. Poewe,et al.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[66]  M. Carlier.  Control of actin dynamics. , 1998, Current opinion in cell biology.

[67]  U S Nayak,et al.  Balance in elderly patients: the "get-up and go" test. , 1986, Archives of physical medicine and rehabilitation.

[68]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[69]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[70]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[71]  R. Mamillapalli,et al.  Systemic Inflammation Induced by microRNAs: Endometriosis-Derived Alterations in Circulating microRNA 125b-5p and Let-7b-5p Regulate Macrophage Cytokine Production , 2018, The Journal of clinical endocrinology and metabolism.

[72]  T. Svitkina.  The Actin Cytoskeleton and Actin-Based Motility. , 2018, Cold Spring Harbor perspectives in biology.

[73]  Shalini Jha,et al.  The diagnosis of Parkinson's disease. , 2003, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.